A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of AF-130 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2016
At a glance
- Drugs AF 130 (Primary)
- Indications Hypertension; Migraine
- Focus Adverse reactions
- Sponsors Afferent Pharmaceuticals
- 27 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2016.
- 18 May 2016 According to a Afferent Pharmaceuticals media release, status changed from recruiting to completed.
- 11 Dec 2015 New trial record